SIIC Deepens 'Hong Kong Incubation, Shanghai Transformation' Strategy with New Biopharma Innovations and IPO Filing

On the afternoon of June 27, Shanghai Industrial Investment (Holdings) Co., Ltd. (SIIC) held its Innovation Development and Talent Work Conference simultaneously in Shanghai and Hong Kong. Centered on the theme “Smart Innovation at SIIC: Gathering Talent to Lead the Way,” the Group unveiled multiple innovation achievements in Shanghai and Hong Kong across the fields of life health, environmental health, talent development, smart cities, and future industries.

Academicians of the Chinese Academy of Sciences, such as Chen Kaixian; President of Shanghai Jiao Tong University, Ding Kuiling; Secretary for Innovation, Technology and Industry of Hong Kong, Professor Sun Dong; Chief Executive Officer of Hong Kong Science and Technology Parks Corporation, Mr. Huang Keqiang; President of the Hong Kong Biomedical Innovation Association, Dr. Lu Yulin; and Chair Professor at the Institute of Emerging Technologies of The University of Hong Kong, Professor Xi Ning, along with other representatives from government agencies, enterprises, scientists, university scholars, and industrial parks in Shanghai and Hong Kong, extended their congratulations via video message.Affirming the significant value of Shanghai Industrial Holdings (SIIC) in building a cross-border cooperation ecosystem and promoting collaborative innovation between Shanghai and Hong Kong, we look forward to SIIC continuing to play its leading role as an industry pioneer, deepening the integration of industrial resources and scientific research advantages between Shanghai and Hong Kong, and injecting sustained momentum into the sci-tech innovation ecosystems of both regions.

Shanghai Industrial Holdings (SIIC) has always regarded deepening Shanghai-Hong Kong collaboration as its core mission, actively building bridges for the flow of innovative factors between the two regions and making numerous attempts to promote Hong Kong’s innovation and technology industry. It has jointly launched the Hong Kong Biotechnology Fund with the Hong Kong University of Science and Technology, focusing on the translation and incubation of scientific research achievements from universities in Hong Kong and the Greater Bay Area. Together with the University of Hong Kong and the Shanghai Industrial Technology Research Institute, it has established a Future Intelligent Technology Incubator to accelerate the integrated application of AI and robotics technologies. Meanwhile, SIIC has deepened its cooperation with the Hong Kong Science and Technology Parks Corporation to jointly create the Shanghai-Hong Kong joint incubator “01LABS@Hong Kong,” facilitating the “incubation in Hong Kong, commercialization in Shanghai” value chain.

More encouragingly, SIIC Group has successively launched multiple specialized investment platforms focused on innovation-driven sectors, including the Shanghai Biopharmaceutical Fund, the Innovation Commercialization Fund, the M&A Fund, the Hong Kong Biotech Fund, and the Green Tech CVC Fund. Through strategic investments, these platforms have facilitated the establishment of more than ten innovative pharmaceutical and medical device companies in Hong Kong, leveraging the complementary strengths of Shanghai and Hong Kong to jointly support the development of the biotechnology industry.

Looking ahead, Shanghai Industrial Investment (Holdings) Co., Ltd. (SIIC) will continue to deepen strategic collaboration between Shanghai and Hong Kong. Leveraging multiple early-stage funds established in Hong Kong, SIIC will accelerate the commercialization of innovative achievements and support the development of Hong Kong as an international innovation and technology hub. By fully harnessing the synergistic advantages of “technology + finance + industry,” SIIC aims to integrate the innovation, industrial, and talent chains of both cities, fostering mutual learning and complementary strengths between the “Pearl of the Orient” (Shanghai) and the “Oriental Pearl” (Hong Kong). This effort will write a new chapter in Shanghai-Hong Kong cooperation, serving national strategies and leading industrial transformation.

SIIC’s Portfolio Company Logo Wall showcased the brands of companies currently invested in by its two major fund matrices: the SHC Biopharmaceutical Series Fund and the STC SIIC Technology Fund, highlighting its dual investment focus on biopharmaceuticals and green technology. As representative portfolio companies, ShuRui and Guangmai Medical presented their core products on-site. Dr. Shou Jianyong, Founder, CSO, and President of R&D at Yinuo Pharmaceutical, delivered a speech titled “AI-Empowered Biopharmaceuticals: Breaking Boundaries and Advancing Innovative Drug Development.” Medbanks Health, as an outstanding case of innovative practice, also shared in-depth insights at the conference.